Sehouli J - Search Results

1

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.

Willing EM, Vollbrecht C, Vössing C, Weist P, Schallenberg S, Herbst JM, Schatz S, Jóri B, Bataillon G, Harter P, Salutari V, Martin AG, Vergote I, Colombo N, Roeper J, Berg T, Berger R, Kah B, Noettrup TJ, Falk M, Arndt K, Polten A, Ray-Coquard I, Selzam F, Pirngruber J, Schmidt S, Hummel M, Tiemann M, Horst D, Sehouli J, Pujade-Lauraine E, Tiemann K, Braicu EI, Heukamp LC. Willing EM, et al. Among authors: sehouli j. Cancers (Basel). 2023 Jun 30;15(13):3445. doi: 10.3390/cancers15133445. Cancers (Basel). 2023. PMID: 37444554 Free PMC article.

2

Expression of IL-10 in patients with ovarian carcinoma.

Mustea A, Könsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J. Mustea A, et al. Among authors: sehouli j. Anticancer Res. 2006 Mar-Apr;26(2C):1715-8. Anticancer Res. 2006. PMID: 16617566 Free article.

3

Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study.

Mustea A, Sehouli J, Fabjani G, Koensgen D, Möbus V, Braicu EI, Pirvulescu C, Thomas A, Tong D, Zeillinger R. Mustea A, et al. Among authors: sehouli j. Anticancer Res. 2007 May-Jun;27(3B):1527-30. Anticancer Res. 2007. PMID: 17595771 Free article.

4

A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.

Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. Vergote I, et al. Among authors: sehouli j. Eur J Cancer. 2009 May;45(8):1415-23. doi: 10.1016/j.ejca.2008.12.013. Epub 2009 Jan 23. Eur J Cancer. 2009. PMID: 19168349 Clinical Trial.

5

Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue.

Sinn BV, Darb-Esfahani S, Wirtz RM, Faggad A, Weichert W, Buckendahl AC, Noske A, Müller BM, Budczies J, Sehouli J, Braicu EI, Dietel M, Denkert C. Sinn BV, et al. Among authors: sehouli j. Virchows Arch. 2009 Dec;455(6):461-7. doi: 10.1007/s00428-009-0851-6. Epub 2009 Nov 13. Virchows Arch. 2009. PMID: 19911196

6

Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients.

Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C. Sehouli J, et al. J Surg Oncol. 2010 Nov 1;102(6):656-62. doi: 10.1002/jso.21652. J Surg Oncol. 2010. PMID: 20734422

7

Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients.

Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J. Fotopoulou C, et al. Among authors: sehouli j. Eur J Surg Oncol. 2010 Dec;36(12):1202-10. doi: 10.1016/j.ejso.2010.09.008. Epub 2010 Sep 22. Eur J Surg Oncol. 2010. PMID: 20864305 Free article.

8

What are the individual perceptions of patients with borderline tumours of the ovary in regard to pathogenesis and prognosis? A structured survey on 60 women.

Fotopoulou C, Bugariu M, Braicu EI, Lichtenegger W, Sehouli J. Fotopoulou C, et al. Among authors: sehouli j. J Psychosom Obstet Gynaecol. 2010 Dec;31(4):265-72. doi: 10.3109/0167482X.2010.528091. Epub 2010 Nov 2. J Psychosom Obstet Gynaecol. 2010. PMID: 21039327

9

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.

Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Harter P, et al. Among authors: sehouli j. Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd. Int J Gynecol Cancer. 2011. PMID: 21270612

10

Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics.

Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, Weichert W, Sehouli J, Braicu E, Dietel M, Denkert C. Buckendahl AC, et al. Among authors: sehouli j. Oncol Rep. 2011 Apr;25(4):1005-12. doi: 10.3892/or.2011.1162. Epub 2011 Jan 25. Oncol Rep. 2011. PMID: 21271224

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

766 results

Search Page